Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect PK Study of SY-5007 in Healthy Chinese Subjects
NCT06325761Phase 1Not yet recruiting
- Sponsor
- Shouyao Holdings
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotetinib in solid tumor, non-small cell lung cancer (NSCLC) and Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Shouyao Holdings. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
sotetinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT06325761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325761.